ARS PHARMACEUTICALS ($SPRY) posted quarterly earnings results on Wednesday, May 14th. The company reported earnings of -$0.35 per share, beating estimates of -$0.35 by $0.00. The company also reported revenue of $7,970,000, beating estimates of $7,631,130 by $338,870.
You can see Quiver Quantitative's $SPRY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARS PHARMACEUTICALS Insider Trading Activity
ARS PHARMACEUTICALS insiders have traded $SPRY stock on the open market 37 times in the past 6 months. Of those trades, 0 have been purchases and 37 have been sales.
Here’s a breakdown of recent trading of $SPRY stock by insiders over the last 6 months:
- JUSTIN CHAKMA (Chief Business Officer) has made 0 purchases and 11 sales selling 529,245 shares for an estimated $7,087,279.
- LAURA SHAWVER has made 0 purchases and 9 sales selling 400,002 shares for an estimated $5,034,901.
- RICHARD E LOWENTHAL (PRESIDENT AND CEO) has made 0 purchases and 6 sales selling 300,000 shares for an estimated $3,878,480.
- SARINA TANIMOTO (CHIEF MEDICAL OFFICER) has made 0 purchases and 6 sales selling 300,000 shares for an estimated $3,878,480.
- BRIAN DORSEY (Chief Operating Officer) has made 0 purchases and 2 sales selling 40,000 shares for an estimated $493,858.
- ERIC KARAS (Chief Commercial Officer) has made 0 purchases and 3 sales selling 20,000 shares for an estimated $280,423.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARS PHARMACEUTICALS Hedge Fund Activity
We have seen 83 institutional investors add shares of ARS PHARMACEUTICALS stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. added 3,807,074 shares (+5168.4%) to their portfolio in Q4 2024, for an estimated $40,164,630
- ALYESKA INVESTMENT GROUP, L.P. added 1,128,724 shares (+903.0%) to their portfolio in Q4 2024, for an estimated $11,908,038
- STATE STREET CORP added 700,359 shares (+34.2%) to their portfolio in Q4 2024, for an estimated $7,388,787
- LEVIN CAPITAL STRATEGIES, L.P. added 696,974 shares (+149.0%) to their portfolio in Q1 2025, for an estimated $8,767,932
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 563,270 shares (-5.1%) from their portfolio in Q4 2024, for an estimated $5,942,498
- CITADEL ADVISORS LLC added 552,957 shares (+219.0%) to their portfolio in Q4 2024, for an estimated $5,833,696
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 551,651 shares (-84.5%) from their portfolio in Q4 2024, for an estimated $5,819,918
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $SPRY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Outperform" rating on 03/07/2025
- Raymond James issued a "Strong Buy" rating on 01/14/2025
To track analyst ratings and price targets for ARS PHARMACEUTICALS, check out Quiver Quantitative's $SPRY forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
